AGIO
Agios Pharmaceuticals, Inc.
$28.14
-0.65
(-2.26%)
Mkt Cap
1.67B
Volume
751,629
52W Range
22.24-46
Sector
Healthcare
Beta
0.58
EPS (TTM)
-7.25
P/E Ratio
-3.82
Revenue (TTM)
66.05M
Rev Growth (5Y)
-2.8%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
$132.72
Undervalued · Strong
78.8% below fair value
AlphaQuality · Grade · Gated
F
Stable Earnings Power
30.0 / 100 pillar composite (overridden)
Company Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 54.03M | 36.50M | 26.82M | 14.24M | 0 | 0 | 117.91M | 94.39M | 43.01M | 69.89M | 59.12M | 65.36M |
| Net Income | (412.78M) | 673.73M | (352.09M) | (231.80M) | 1.60B | (327.37M) | (411.47M) | (346.03M) | (314.67M) | (198.47M) | (117.73M) | (53.50M) |
| EPS | -7.12 | 11.86 | -6.33 | -4.23 | -6.36 | -4.74 | -6.61 | -6.03 | -6.75 | -5.07 | -3.15 | -1.59 |
| Free Cash Flow | (377.29M) | (391.53M) | (297.06M) | (314.36M) | (413.06M) | (304.87M) | (382.79M) | (311.41M) | (289.86M) | 28.65M | N/A | N/A |
| FCF / Share | -6.51 | -6.89 | -5.34 | -5.74 | -6.83 | -4.42 | -6.38 | -5.42 | -6.22 | 0.73 | N/A | N/A |
| Operating CF | (372.98M) | (389.84M) | (296.06M) | (309.48M) | (407.32M) | (290.76M) | (370.62M) | (304.42M) | (285.23M) | 38.56M | N/A | N/A |
| Total Assets | 1.30B | 1.66B | 937.12M | 1.24B | 1.44B | 852.95M | 890.74M | 858.46M | 614.40M | 619.09M | N/A | N/A |
| Total Debt | 62.02M | 56.99M | 72.00M | 85.66M | 97.09M | 105.20M | 113.66M | 0 | 0 | 0 | N/A | N/A |
| Cash & Equiv | 89.13M | 76.25M | 88.20M | 139.26M | 203.13M | 127.44M | 80.93M | 805.42M | 567.75M | 573.56M | N/A | N/A |
| Book Value | 1.19B | 1.54B | 811.02M | 1.10B | 1.29B | 399.50M | 640.53M | 687.54M | 375.50M | 358.59M | N/A | N/A |
| Return on Equity | -0.35 | 0.44 | -0.43 | -0.21 | 1.24 | -0.82 | -0.64 | -0.50 | -0.84 | -0.55 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.75M | 19.97M | 12.88M | 12.46M | 8.73M | 10.73M | 8.96M | 8.62M | 8.19M | 7.10M | 7.40M | 6.71M |
| Net Income | (99.11M) | (108.04M) | (103.43M) | (112.02M) | (89.29M) | (96.52M) | 947.91M | (96.12M) | (81.55M) | (95.94M) | (91.32M) | (83.81M) |
| EPS | -1.69 | -1.85 | -1.78 | -1.93 | -1.55 | -1.69 | 16.65 | -1.69 | -1.45 | -1.72 | -1.64 | -1.51 |
| Free Cash Flow | (119.69M) | (97.33M) | (89.71M) | (78.00M) | (112.25M) | (134.13M) | (84.64M) | (72.75M) | (100.01M) | (72.72M) | (62.01M) | (66.75M) |
| FCF / Share | -2.04 | -1.67 | -1.54 | -1.35 | -1.95 | -2.35 | -1.49 | -1.28 | -1.77 | -1.30 | -1.11 | -1.20 |
| Operating CF | (118.92M) | (96.21M) | (88.15M) | (77.12M) | (111.49M) | (133.17M) | (84.22M) | (72.59M) | (99.87M) | (72.49M) | (61.64M) | (66.75M) |
| Total Assets | 1.18B | 1.30B | 1.39B | 1.47B | 1.56B | 1.66B | 1.79B | 773.06M | 849.71M | 937.12M | 1.01B | 1.09B |
| Total Debt | 35.74M | 40.21M | 44.52M | 48.76M | 52.94M | 56.99M | 60.83M | 64.62M | 68.35M | 72.00M | 75.50M | 78.95M |
| Cash & Equiv | 113.60M | 89.13M | 92.71M | 80.87M | 78.96M | 76.25M | 253.73M | 84.52M | 118.76M | 88.20M | 64.33M | 84.75M |
| Book Value | 1.11B | 1.19B | 1.28B | 1.37B | 1.47B | 1.54B | 1.63B | 660.51M | 743.92M | 811.02M | 886.84M | 964.24M |
| Return on Equity | -0.09 | -0.09 | -0.08 | -0.08 | -0.06 | -0.06 | 0.58 | -0.15 | -0.11 | -0.12 | -0.10 | -0.09 |
AGIO News
Avanzanite Bioscience's Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia
Agios' PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia
Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances
Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease
Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease
Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease
Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias
Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026)
AGIO Beats on Q1 Earnings & Sales, Stock Up 13% on New Drug Momentum
Why Agios Pharmaceuticals Stock Zoomed to a 13% Gain on Wednesday